Entrada Therapeutics, Inc. (TRDA)

NASDAQ: TRDA · Real-Time Price · USD

5.86

+0.06 (0.95%)

Sep 29, 2025, 3:15 PM EDT - Market open

Entrada Therapeutics Employees

Entrada Therapeutics had 183 employees as of December 31, 2024. The number of employees increased by 24 or 15.09% compared to the previous year.

Employees

183

Change (1Y)

24

Growth (1Y)

15.09%

Revenue / Employee

$434,295

Profits / Employee

-$400,836

Market Cap

208.16M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	183	24	15.09%
Dec 31, 2023	159	29	22.31%
Dec 31, 2022	130	16	14.04%
Dec 31, 2021	114	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

TRDA News

4 days ago - Entrada Therapeutics, Inc. - Special Call - Seeking Alpha
24 days ago - Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program - GlobeNewsWire
26 days ago - Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
7 weeks ago - Entrada Therapeutics Reports Second Quarter 2025 Financial Results - GlobeNewsWire
4 months ago - Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors - GlobeNewsWire
4 months ago - Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping - GlobeNewsWire
5 months ago - Entrada Therapeutics Reports First Quarter 2025 Financial Results - GlobeNewsWire
6 months ago - Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping - GlobeNewsWire